Business
Karyopharm Announces Further Transition of Co-Founders Sharon Shacham PhD, MBA and Michael Kauffman, MD, PhD and appointment of Reshma Rangwala, MD, PhD as Chief Medical Officer
- Formerly of Aravive, Genmab and Merck & Co., Dr. Rangwala will Lead Karyopharm's Clinical Development Programs and Strategy - - As Part of Karyopharm's
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"- Formerly of Aravive, Genmab and Merck & Co., Dr. Rangwala will Lead Karyopharm's Clinical Development Programs and Strategy -\n- As Part of Karyopharm's Evolution, Co-Founders Dr. Shacham and Dr. Kauffman Will Transition Out of the Company on May 31, 2022 - \n- Dr. Shacham Will Continue her Engagement with the Company's Scientific Advisory Board and Serve in an Advisory Capacity -\nNEWTON, Mass., March 29, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Reshma Rangwala, MD, PhD, as the Company's Chief Medical Officer. Dr. Rangwala will join the Company in mid-April 2022 and will be responsible for leading the Company's clinical development programs and strategy.\n\"We are delighted to have Dr. Rangwala join our team at this transformative point in our Company's evolution,\" said Richard Paulson, President and Chief Executive Officer of Karyopharm. \"Her extensive experience developing and executing clinical strategies for novel oncology therapeutics, as well as engaging regulators and the medical community at all stages of development, will be of immeasurable value as we accelerate our four core programs in clinical development.\"\n\"I am thrilled to join the Karyopharm team at this exciting and pivotal time in the company's growth,\" said Dr. Rangwala. \"Given their unique mechanism of action, both XPOVIO® (selinexor) and eltanexor have significant potential for patients battling an array of cancer types and I look forward to leading the future clinical development and advancing both assets through the clinic. I am impressed with both the team and the science of XPO1 inhibition and I am excited to realize the potential of these important therapies.\"\nDr. Rangwala brings to Karyopharm more than a decade of experience in oncology and drug development. She was most recently the Chief Medical Officer at Aravive where she led the clinical development of batiraxcept across multiple tumor types. Prior to Aravive, she served as Vice President, Medical, at Genmab where she led the clinical development program for a first-in-class antibody drug conjugate and managed clinical strategy, protocol development, data monitoring, data analysis, study report authoring, and biologic licensing application preparation...